Among 180 DMARD-naive patients with early RA, an aggressive treat-to-target strategy based on methotrexate and intra-articular triamcinolone resulted in similar treatment profiles and clinical responses at 2 years, regardless of whether patients also received adalimumab or placebo during the first year. Adalimumab was (re)initiated if active disease recurred. Worsening of erosion scores was slightly reduced in the adalimumab-withdrawal group.
References
Hørslev-Petersen, K. et al. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Ann. Rheum. Dis. doi:10.1136/annrheumdis-2015-208166
Rights and permissions
About this article
Cite this article
OPERA regimen gives excellent RA control (NCT00660647). Nat Rev Rheumatol 11, 682 (2015). https://doi.org/10.1038/nrrheum.2015.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.153
